From innovation to access: bridging gaps in scalability and cold chain precision logistics for advanced therapies

Jokūbas Leikauskas, Editor, BioInsights, speaks to Rohin Iyer, Senior Director, Global Cell and Gene Therapy Operations, Marken, about addressing the complex logistics of cell and gene therapies through global infrastructure, precision, and advanced technologies. They also discuss evolving cold chain needs, regulatory and geopolitical challenges, and the need for scalability. 

Chapters

• 1:19 Starting with Marken’s role in the CGT ecosystem, how does your team support the unique logistic needs of CGT’s, particularly when it comes to ensuring global delivery of uncompromised product integrity?
• 2:47 Following on, what recent innovations or regulatory shifts are having the biggest impact on how CGTs are developed, transported, and delivered?
• 5:58 As the complexity of CGT logistics continues to grow, what are the most pressing bottlenecks or vulnerabilities of today’s cold chain infrastructure and how can we start to solve them?
• 8:13 With this in mind, how does Marken define precision in this context, and what technologies or process are central to achieving that level of control, visiblity, and responsiveness?
• 12:05 Scale is often a limiting factor for emerging therapies. What does scalable logistics look like in the CGT space, especially when dealing with personalized patient specific treatment across boarders?
• 15:34 Looking ahead, the CGT pipeline is only getting more crowded and complex. What disruptions do you foresee over the next 3-5 years, and how is Marken evolving to stay ahead of those changes?